TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02441673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam
Description: Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Tramadol 1mg/kg would be made up to 10mls using sterile water for injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10mg would be given morning of surgery as a prokinetic premedication for all patients.
Study: NCT01660724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided arterial puncture
Description: Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arterial puncture technique
Description: Arterial puncture is performed using the conventional technique
Study: NCT02441673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10mg would be given morning of surgery as a prokinetic premedication for all patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
Study: NCT02751723

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires
Study: NCT02441673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: 25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: 25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Would be used for all patients following delivery of the baby to aid contraction of the uterus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: Would be used for all patients following delivery of the baby to aid contraction of the uterus.
Study: NCT03354442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Fixed Mandibular Retractor Appliance
Description: All patients with Class III malocclusion will be treated using the Modified Fixed Mandibular Retractor Appliance
Study: NCT02344433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VICKY
Description: Relational agent/virtual counselor

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MFHP
Description: US Surgeon General's family history tool
Study: NCT02887937

Intervention type: DRUG
Intervention: Definity
Description: The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.

Intervention type: DRUG
Intervention: Definity
Description: The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.

Intervention type: DRUG
Intervention: Definity
Description: The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.

Intervention type: DRUG
Intervention: Definity
Description: The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
Study: NCT02717663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goals
Description: Prescribed goals change daily based on participant's performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Goals
Description: Prescribed goals change daily based on participant's performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Goals
Description: Prescribed goals remain the same throughout study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Static Goals
Description: Prescribed goals remain the same throughout study

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed (non-contingent) Incentives
Description: Incentives are provided on bi-monthly basis for participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed (non-contingent) Incentives
Description: Incentives are provided on bi-monthly basis for participation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Micro-Incentives
Description: Incentives are provided immediately for each goal attained

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Micro-Incentives
Description: Incentives are provided immediately for each goal attained
Study: NCT03165539

Intervention type: DEVICE
Intervention: Cerebral oxygen saturation monitoring
Description: Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
Study: NCT00614705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-797804
Description: 6 mg dose in oral capsule form, once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule form, once daily for 28 days
Study: NCT01432834

Intervention type: OTHER
Group type: OTHER
Intervention: Laser in situ keratomileusis (LASIK)
Description: During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH \& Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Photorefractive keratectomy (PRK)
Description: The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected.
Study: NCT02676856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell microtransplantation-long-term
Description: Stem cell infusion are administrated once three months for 3 times with the cell count of 3\*10\^8/kg/once.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hematopoietic stem cell microtransplantation-short-term
Description: Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3\*10\^8/kg/once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning for CR group
Description: For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning for Non-CR group
Description: For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
Study: NCT05829707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium
Description: A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine bolus analgesia
Description: The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. A first dose of local anesthetic was delivered at the end of the surgical procedure to test catheter placement. Bolus doses of local anesthetics based on the patients' body weight were thereafter delivered by the nurse in 8 hours intervals.~All patients were assessed before the surgical procedure and hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine PCA group
Description: The levobupivacaine dose was calculated by a doctor. A wound infiltration catheter was inserted at the end of the surgical procedure by a surgeon. Levobupivacaine was delivered by PCA pump (CADD - Legacy® PCA Pump, Model 6300, Smiths Medical MD, Inc., St. Paul, USA). A drug delivery was started at the end of the surgical procedure.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for persisting pain \>4 on the VAS, and meperidine 20-30 mg for VAS \>or = 4.
Study: NCT04622033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: brodalumab 210mg at week 0, 1, 2 and then every 2 weeks up to 24 weeks.
Study: NCT03166163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azadirachta indica
Description: Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
Study: NCT02868177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Totum-63
Description: Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
Study: NCT03990857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care protocol in new diagnosis of Type 2 Diabetes Mellitus and associated comorbidities in Primary Care
Description: This comprehensive intervention is developed in a structured way in the Primary care nurse office. 5 individual intensive visits will be carried out with a weekly or bi-weekly frequency (according to the learning process) to work for an integral care and to transmit the knowledge and skills required. The maximum time expected to receive this 5 visits is 3 months. At least one of the visits, preferably the one that deals with dietary aspects, the patient is asked to be visited with the partner, child or cohabiting person. The research team elaborated the support material with the minimum contents that every patient that begins with T2DM and other chronic pathologies should know. It allows incorporating cultural and emotional aspects. It was agreed with hospital diabetes educators and family doctors. A graphic designer gave an enticing design. A group of patients verified their utility and intelligibility. It is delivered to the person and discussed during the intensification.
Study: NCT01233453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the everolimus eluting ® stent
Description: stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the Biolimus A9 eluting NOBORI® stent
Description: stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
Study: NCT02920086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Education Program
Description: * The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention~* Nutritional education will be provided to ICU patents' families by a dietitian~* Tracking of nutritional information by family~* Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support Program
Description: * Families will be provided with a web-based decision support tool (My ICU Guide)~* Families will meet with the ICU medical team early in ICU stay to review goals of care
Study: NCT03085758

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adrecizumab
Description: Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single i.v. dose of placebo (control group)
Study: NCT00324129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 given orally three times per week.
Study: NCT02420132

Intervention type: OTHER
Intervention: Ranibizumab
Description: Ranibizumab administered as part of standard-of-care

Intervention type: OTHER
Intervention: Ranibizumab
Description: Ranibizumab administered as part of standard-of-care
Study: NCT01386658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icatibant
Description: Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
Study: NCT00119041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Diabetes Treatment Satisfaction Questionnaire
Description: A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Empowerment Scale
Description: A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBOC's undergo half-day joint-clinics via teleconference
Description: A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
Study: NCT02950402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two Dried Plums per day
Description: Subjects will consume Two Dried Plums per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two Dried Plums per day
Description: Subjects will consume Two Dried Plums per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six Dried Plums per day
Description: Subjects will consume Six Dried Plums per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Six Dried Plums per day
Description: Subjects will consume Six Dried Plums per day
Study: NCT01448122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avene Compact Honey SPF 50
Description: Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
Study: NCT02610153

Intervention type: DRUG
Intervention: Vitamin K Antagonist
Description: The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
Study: NCT01765868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban
Description: Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
Study: NCT02423018

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pregabalin
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Study: NCT00288795

Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: Therapeutic Touch

Intervention type: OTHER
Group type: OTHER
Intervention: Polarity Therapy
Description: Use of energy fields to alleviate distress and achieve balance in the body
Study: NCT04154332

Intervention type: OTHER
Intervention: Sample collection
Description: Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.

Intervention type: OTHER
Intervention: Sample collection
Description: Blood, urine, placental samples, and the patient's vascular reactivity will be collected from each person enrolled in this study.
Study: NCT02643160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Trunk Training
Description: The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
Study: NCT00393328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Ritonavir
Description: Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir + Ritonavir
Description: Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
Study: NCT05975801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Cupping Therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment (hotpack, transcutaneous electrical nerve stimulation(TENS), ultrasound